key: cord-0734966-ht2fxdtv
authors: Hosogaya, Naoki; Miyazaki, Taiga; Fukushige, Yuri; Takemori, Sachiko; Morimoto, Shinpei; Yamamoto, Hiroshi; Hori, Makoto; Kurokawa, Tomoya; Kawasaki, Yohei; Hanawa, Michiko; Fujii, Yasuhisa; Hanaoka, Hideki; Iwami, Shingo; Watashi, Koichi; Yamagoe, Satoshi; Miyazaki, Yoshitsugu; Wakita, Takaji; Izumikawa, Koichi; Yanagihara, Katsunori; Mukae, Hiroshi; Kohno, Shigeru
title: Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial
date: 2021-04-28
journal: Trials
DOI: 10.1186/s13063-021-05282-w
sha: 2946c29f5f25c3ed5996a9fb4e276fbec77f7c5a
doc_id: 734966
cord_uid: ht2fxdtv

OBJECTIVES: The aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19. TRIAL DESIGN: The study is designed as a multicenter, open-label, blinded outcome assessment, parallel group, investigator-initiated, exploratory, randomized (1:1 ratio) controlled clinical trial. PARTICIPANTS: Asymptomatic and mild COVID-19 patients will be enrolled in 10 university and teaching hospitals in Japan. The inclusion and exclusion criteria are as follows: 1. Japanese male or female patients aged ≥ 20 years. 2. SARS-CoV-2 detected from a respiratory tract specimen (e.g., nasopharyngeal swab or saliva) using PCR, LAMP, or an antigen test within 3 days before obtaining the informed consent. 3. Provide informed consent. 1. Symptoms developed ≥ 8 days prior to enrolment. 2. SpO(2) < 96 % (room air). 3. Any of the following screening criteria: a. ALT or AST ≥ 5 × upper limit of the reference range. b. Child-Pugh class B or C. c. Serum creatinine ≥ 2 × upper limit of the reference range and creatinine clearance < 30 mL/min: (4).. Poorly controlled diabetes (random blood glucose ≥ 200 mg/dL or HbA1c ≥ 7.0%, despite treatment); (5).. Unsuitable serious complications based on the assessment of either the principal investigator or the sub-investigator; (6).. Hemophiliac or patients with a marked hemorrhagic tendency; (7).. Severe diarrhea; (8).. Hypersensitivity to the investigational drug; (9).. Breastfeeding or pregnancy; (10).. With childbearing potential and rejecting contraceptive methods during the study period from the initial administration of the investigational drug; (11).. Receiving rifampicin within the previous 2 weeks; (12).. Participated in other clinical trials and received drugs within the previous 12 weeks; (13).. Undergoing treatment for HIV infection; (14).. History of SARS-CoV-2 vaccination or wishes to be vaccinated against SARS-CoV-2; (15).. Deemed inappropriate (for miscellaneous reasons) based on the assessment of either the principal investigator or the sub-investigator. INTERVENTION AND COMPARATOR: Patients who meet the inclusion criteria and do not meet any of the exclusion criteria will be randomized to either the nelfinavir group or the symptomatic treatment group. The nelfinavir group will be administered 750 mg of nelfinavir orally, three times daily for 14 days (treatment period). However, if a participant tests negative on two consecutive PCR tests of saliva samples, administration of the investigational drug for that participant can be discontinued at the discretion of the investigators. The symptomatic treatment group will not be administered the investigational drug, but all other study procedures and conditions will be the same for both groups for the duration of the treatment period. After the treatment period of 14 days, each group will be followed up for 14 days (observational period). MAIN OUTCOMES: The primary endpoint is the time to negative conversion of SARS-CoV-2. During the study period from Day 1 to Day 28, two consecutive negative PCR results of saliva samples will be considered as the negative conversion of the virus. The secondary efficacy endpoints are as follows: For patients with both asymptomatic and mild disease: area under the curve of viral load, half decay period of viral load, body temperature at each time point, all-cause mortality, incidence rate of pneumonia, percentage of patients with newly developed pneumonia, rate of oxygen administration, and the percentage of patients who require oxygen administration. For asymptomatic patients: incidence of symptomatic COVID-19, incidence of fever (≥ 37.0 °C for two consecutive days), incidence of cough For patients with mild disease: incidence of defervescence (< 37.0 °C), incidence of recovery from clinical symptoms, incidence of improvement of each symptom The secondary safety endpoints are adverse events and clinical examinations. RANDOMIZATION: Patients will be randomized to either the nelfinavir group or the symptomatic treatment group using the electric data capture system (1:1 ratio, dynamic allocation based on severity [asymptomatic], and age [< 60 years]). BLINDING (MASKING): Only the assessors of the primary outcome will be blinded (blinded outcome assessment). NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The sample size was determined based on our power analysis to reject the null hypothesis, S (t | z =1) = S (t | z = 0) where S is a survival function, t is time to negative conversion, and z denotes randomization group, by the log-rank test with a two-sided p value of 0.05. We estimated viral dynamic parameters by fitting a nonlinear mixed-effects model to reported viral load data, and simulated our primary endpoint from viral-load time-courses that were realized from sets of viral dynamics parameters sampled from the estimated probability distribution of the parameters (sample size: 2000; 1000 each for randomization group). From this estimation of the hazard ratio between the randomization groups for the event of negative conversion using this simulation dataset, the required number of events for rejecting our null hypothesis with a power of 0.80 felled 97.345 by plugging the estimated hazard ratio, 1.79, in Freedman’s equation. Therefore, we decided the required number of randomizations to be 120 after consideration of the frequency of censoring and the anticipated rate of withdrawal caused by factors such as withdrawal of consent. TRIAL STATUS: Protocol version 6.0 of February 12, 2021. Recruitment started on July 22, 2020 and is anticipated to be completed by March 31, 2022. TRIAL REGISTRATION: This trial was registered in Japan Registry of Clinical Trials (jRCT) (jRCT2071200023) on 21 July 21, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05282-w.

から nonlinear mixed effect model を用い てウイルス動態パラメータ(the rate constant for virus infection, the death rate of infected cells, the maximum viral replication rate for coronavirus infections, the initial number of uninfected target cells) 21 

-31 -7.5.1 薬物誘発性肝障害の可能性(Hy's Law)

World Health Organization: Novel coronavirus (2019-nCoV) situation report-1. 21

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

A novel coronavirus from patients with pneumonia in China

年 2 月 12 日作成)

Clinical Characteristics of Coronavirus Disease 2019 in China

World Health Organization: Novel coronavirus (2019-nCoV) situation report-46

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering

Compassionate Use of Remdesivir for Patients with Severe Covid-19

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

Viral dynamics in mild and severe cases of COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Virological assessment of hospitalized patients with COVID-2019

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea

Modelling SARS-CoV-2 Dynamics: Implications for Therapy. MedRxiv

Royal College of Physicians National Early Warning Score (NEWS) 2: Standardising the assessment of acute illness severity in the NHS. Updated reporting of a work party London: RCP

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application